Literature DB >> 7774836

The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients.

M P Burger1, H Hollema, A G Emanuels, M Krans, E Pras, J Bouma.   

Abstract

The purpose of this study was to analyze (1) the prognostic factors for survival of T1 and T2 carcinoma patients and (2) the impact of the initial groin node status for the time to recurrence and site of recurrence. We performed a follow-up study on 190 women with a T1 or T2 squamous cell carcinoma of the vulva. Data were obtained on age and general medical condition, the clinical and histological characteristics of the primary tumor and the inguinofemoral lymph nodes, treatment, recurrences, and survival. The standard treatment was radical vulvectomy with bilateral inguinofemoral lymphadenectomy supplemented with postoperative radiotherapy to the primary site, groin, and pelvic side walls if groin metastases were present. Compared to patients without lymph node metastases in the groin, the relative risk of dying within a given time period was estimated to be 2.47 (limits of the 95% confidence interval: 1.24, 4.93) and 9.69 (3.90, 24.03) for patients with unilateral and bilateral node metastases, respectively. The number of metastatic lymph nodes or their intra- or extranodal growth was not associated with survival. The relative risk of dying within a given time period was 2.71 (1.36, 5.40) for patients with a T2 tumor compared to those with a T1 tumor and 2.37 (1.31, 4.31) for patients with vasoinvasive growth compared to those without capillary-lymphatic tumor infiltration. Tumor thickness, differentiation grade, and multifocal growth did not determine survival. In the multivariate Cox regression analysis, the presence of inguinofemoral lymph node metastases proved to be the most important prognostic factor for patients' survival. Of the 119 patients who underwent lymphadenectomy but in whom no groin node metastases were found, 6 (5%) patients manifested an early recurrence (i.e., residual cancer or a recurrence within 2 years after the diagnosis). In contrast, of the 51 patients with histologically documented groin node metastases, 15 (29.4%) manifested an early recurrence and these recurrences appeared equally distributed over the primary site and other sites.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7774836     DOI: 10.1006/gyno.1995.1151

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  35 in total

1.  The use of SPECT/CT for anatomical mapping of lymphatic drainage in vulvar cancer: possible implications for the extent of inguinal lymph node dissection.

Authors:  Angela Collarino; Maarten L Donswijk; Willemien J van Driel; Marcel P Stokkel; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-30       Impact factor: 9.236

2.  Groin lymphadenectomy with preservation of femoral fascia: total inguinofemoral node dissection for treatment of vulvar carcinoma.

Authors:  Leonardo Micheletti; Fabrizio Bogliatto; Marco Massobrio
Journal:  World J Surg       Date:  2005-10       Impact factor: 3.352

Review 3.  "Unresectable" vulval cancers: is neoadjuvant chemotherapy the way forward?

Authors:  Kathryn Graham; Kevin Burton
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

4.  Management of patients with vulvar cancer: a perspective review according to tumour stage.

Authors:  Linn Woelber; Fabian Trillsch; Lilli Kock; Donata Grimm; Cordula Petersen; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

5.  The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers.

Authors:  Francesco Giammarile; M Fani Bozkurt; David Cibula; Jaume Pahisa; Wim J Oyen; Pilar Paredes; Renato Valdes Olmos; Sergi Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-08       Impact factor: 9.236

6.  Near-infrared fluorescence sentinel lymph node biopsy in vulvar cancer: a randomised comparison of lymphatic tracers.

Authors:  B E Schaafsma; F P R Verbeek; A A W Peters; J R van der Vorst; C D de Kroon; M I E van Poelgeest; J B M Z Trimbos; C J H van de Velde; J V Frangioni; A L Vahrmeijer; K N Gaarenstroom
Journal:  BJOG       Date:  2013-02-19       Impact factor: 6.531

Review 7.  New Directions in Vulvar Cancer Pathology.

Authors:  Anthony Williams; Sheeba Syed; Shireen Velangi; Raji Ganesan
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

8.  Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.

Authors:  Deyin Xing; Yuehua Liu; Hyeon Jin Park; Inji Baek; Hung Tran; Gloria Cheang; Jorge Novo; Jessica Dillon; Andres Matoso; Emily Farmer; Max A Cheng; Ya-Chea Tsai; Kara Lombardo; Michael G Conner; Russell Vang; Chien-Fu Hung; Tzyy-Choou Wu; Wei Song
Journal:  Hum Pathol       Date:  2019-08-19       Impact factor: 3.466

9.  Use of the Sentinel Lymph Node Technique Compared to Complete Inguino-femoral Lymph Node Removal in Patients with Invasive Vulvar Cancer in Germany.

Authors:  F Kramer; H Hertel; P Hillemanns
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-02       Impact factor: 2.915

10.  Sentinel Lymph Node Biopsy in Vulvar Cancer Using Combined Radioactive and Fluorescence Guidance.

Authors:  Floris P R Verbeek; Quirijn R J G Tummers; Daphne D D Rietbergen; Alexander A W Peters; Boudewijn E Schaafsma; Cornelis J H van de Velde; John V Frangioni; Fijs W B van Leeuwen; Katja N Gaarenstroom; Alexander L Vahrmeijer
Journal:  Int J Gynecol Cancer       Date:  2015-07       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.